Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Present at Upcoming Investor Conferences

May 12, 2021 7:30am EDT

Aptose Reports Results for the First Quarter 2021

May 04, 2021 4:01pm EDT

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

Apr 26, 2021 4:02pm EDT

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Apr 08, 2021 7:30am EDT

Aptose Reports Results for the Fourth Quarter and Full Year 2020

Mar 23, 2021 4:01pm EDT

Aptose Expands Senior Leadership Team

Mar 16, 2021 7:30am EDT

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

Mar 02, 2021 4:02pm EST

Aptose Presents Highlights from ASH and Corporate Update Event

Dec 06, 2020 5:30pm EST

Aptose to Hold Corporate Update Sunday, December 6th

Dec 01, 2020 7:30am EST

Aptose Reports Results for the Third Quarter 2020

Nov 10, 2020 4:01pm EST
RSS
  • Prev
    • 1...
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • ...33
    Next
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences